3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
202
Leukemia, Lymphocytic, Chronic, B-Cell
54
Recurrence
37
Neoplasms, Plasma Cell
30
Lymphoma, Mantle-Cell
30
Lymphoma
30
Lymphoma, Follicular
29
Lymphoma, Large B-Cell, Diffuse
27
Leukemia
23
Leukemia, Myeloid, Acute
22
Lymphoma, Non-Hodgkin
21
Lymphoma, B-Cell, Marginal Zone
15
Myelodysplastic Syndromes
13
Hodgkin Disease
12
Waldenstrom Macroglobulinemia
8
Prostatic Neoplasms
8
Lymphoma, T-Cell
8
Smoldering Multiple Myeloma
7
Immunoglobulin Light-chain Amyloidosis
7
Neoplasms
6
Melanoma
6
Lymphoma, B-Cell
6
Hematologic Diseases
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, Large-Cell, Anaplastic
5
Leukemia, Myelomonocytic, Chronic
5
Hematologic Neoplasms
5
Amyloidosis
5
Sezary Syndrome
4
Interventions
Vincristine
2
Inotuzumab Ozogamicin
2
Doxorubicin
2
Dexamethasone
2
Cyclophosphamide
2
pegaspargase
1
merphos
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
azathiopurine
1
auricularum
1
Thioguanine
1
Prednisone
1
Methotrexate
1
Mercaptopurine
1
Leucovorin
1
Lenalidomide
1
Etoposide
1
Cytarabine
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
×
Lenalidomide
×
Clear all
NCT01116193
2017-09-14
RV-405 LAL
Institut de Cancérologie de la Loire
Phase 2
Completed
10 enrolled